FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasnington, b.c. 20040

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person MUELLER PETER						VERTEX PHARMACEUTICALS INC / MA [VRTX]								heck all appl Direc	icable) or r (give title	ig Pers	10% Ov Other (s below)	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED							3. Date of Earliest Transaction (Month/Day/Year) 04/25/2011								EVP, Global R&D, CSO				
130 WAVERLY ST						4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Individual or Joint/Group Filing (Check Applicable ine)					
(Street) CAMBRIDGE MA 02139														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																
		Tal	ole I - No	n-Deriv	vativ	e Se	curit	ties Ac	quired,	Dis	posed o	of, or Be	neficia	lly Owne	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		Benefic Owned	ies :ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) o	r Price		ction(s) 3 and 4)			(Instr. 4)	
Common Stock 04/25/					5/201	2011			М		12,50	0 A	\$16.	32 14	146,235		D		
Common Stock 04/25/					5/201	2011			S ⁽¹⁾		12,50	0 D	\$50) 13	133,735		D		
Common Stock													4,150			I ·	401(k)		
			Table II -								osed of converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of		6. Date Expiration (Month/Da	n Date	of Secur r) Underlyi		ng e Security	8. Price of Derivative Security (Instr. 5)		e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Stock	\$16.32	04/25/2011		T	M			12,500	(2)		07/15/2013	Common	12,500	\$0.00	100,0	00	D		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Fully vested.

Remarks:

Kenneth S. Boger, Attorney-In-

Fact

** Signature of Reporting Person

Date

04/26/2011

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.